Man Kuan Chan

Man Kuan Chan is a distinguished inventor based in Cambridge, GB. He has made significant contributions to the field of biomarker research, particularly in relation to mental health disorders. With a total of 2 patents, his work focuses on innovative methods for diagnosing and monitoring conditions such as schizophrenia.

Latest Patents

Chan's latest patents include groundbreaking inventions that have the potential to transform psychiatric treatment. The first patent, titled "Biomarkers associated with schizophrenia," relates to biomarkers and methods for diagnosing or monitoring schizophrenia, or a predisposition to it. The second patent, "Marker for response to antidepressant therapy," involves the use of ApoA4 as a biomarker for predicting whether a patient will respond to antidepressant treatment. This invention also encompasses methods and kits designed to predict patient responses to such treatments using the identified biomarker.

Career Highlights

Man Kuan Chan is affiliated with the University of Cambridge, where he conducts his research and development activities. His work has garnered attention for its potential impact on improving patient outcomes in mental health care.

Collaborations

Chan collaborates with notable colleagues in his field, including Sabine Bahn and Viktoria Stelzhammer. Their combined expertise enhances the research efforts and innovation in biomarker applications.

Conclusion

In summary, Man Kuan Chan is a prominent inventor whose work in biomarker research is paving the way for advancements in the diagnosis and treatment of mental health disorders. His contributions are vital to the ongoing evolution of psychiatric care.

Profile summary based on public USPTO records.